Alto Neuroscience grants director 10,958 stock options

Alto Neuroscience director Manji Husseini received a stock option grant for 10,958 shares of common stock.

Rhea-AI Filing Summary

Alto Neuroscience director Manji Husseini received a stock option grant for 10,958 shares of common stock. The option has an exercise price of $24.63 per share and expires on May 11, 2036. The shares underlying the option vest on the earlier of the one-year anniversary of the grant date and the company’s next annual meeting, as long as he remains in continuous service. According to the disclosure, the option was issued under the non-employee director compensation policy and no cash consideration was paid for the grant. Following this award, Husseini holds options covering 10,958 shares directly.

Insider Trade Summary

Grant/Award: 10,958 shares

Grant/Award 1 txn

Insider Manji Husseini

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	10,958	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 10,958 contracts (Direct)

Footnotes (2)

1. F1. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.
2. F2. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

Key Figures

Option grant size: 10,958 shares Exercise price: $24.63 per share Expiration date: May 11, 2036 +3 more

6 metrics

Option grant size 10,958 shares Stock Option (right to buy) granted to director

Exercise price $24.63 per share Conversion or exercise price of the stock option

Expiration date May 11, 2036 Option expiration for director stock option grant

Shares underlying option 10,958 shares Underlying common stock tied to the derivative security

Total options held after grant 10,958 shares Total shares subject to options following this transaction

Vesting condition Earlier of 1-year anniversary or next annual meeting Subject to continuous service through vesting date

Key Terms

Stock Option (right to buy), Non-Employee Director Compensation Policy, derivative securities, continuous service, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Non-Employee Director Compensation Policy financial

"issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy"

derivative securities financial

"did not pay any consideration for the derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

underlying security financial

"underlying security shares: 10958.0000"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alto Neuroscience (ANRO) director Manji Husseini report in this Form 4?

Director Manji Husseini reported receiving a stock option grant for 10,958 shares of Alto Neuroscience common stock. The award is a compensation-related grant, not an open-market purchase or sale of shares.

How many Alto Neuroscience (ANRO) shares are covered by the new stock option?

The reported stock option covers 10,958 shares of Alto Neuroscience common stock. These underlying shares represent potential future ownership if the option is exercised at or above the stated exercise price.

What is the exercise price and expiration of Manji Husseini’s Alto Neuroscience option?

The stock option has an exercise price of $24.63 per share and an expiration date of May 11, 2036. Husseini can only benefit from exercising if the market price exceeds this exercise price before expiration.

When do the Alto Neuroscience (ANRO) director stock options vest?

The shares underlying the option vest on the earlier of the one-year anniversary of the grant date and Alto Neuroscience’s next annual meeting. Vesting is conditioned on Husseini’s continuous service with the company through that date.

Did Manji Husseini pay cash for the Alto Neuroscience stock option grant?

No, the filing states the option was issued under Alto Neuroscience’s Non-Employee Director Compensation Policy and was not sold to Husseini. He therefore did not pay any cash consideration for these derivative securities.

Is this Alto Neuroscience (ANRO) Form 4 a buy or sell signal?

The Form 4 reports an acquisition of a stock option grant as director compensation, coded as a grant or award. It is not an open-market buy or sell and is generally considered a routine equity compensation event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manji Husseini

(Last) (First) (Middle)

C/O ALTO NEUROSCIENCE, INC.

650 CASTRO STREET, SUITE 450

(Street)

MOUNTAIN VIEW CALIFORNIA 94041

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$24.63	05/12/2026		A		10,958		(1)	05/11/2036	Common Stock	10,958	$0(2)	10,958	D

Explanation of Responses:

1. The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date.

2. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities.

Remarks:

	/s/ Erin R. McQuade, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)